콘텐츠로 건너뛰기
Merck

830071P

Avanti

Egg Lyso PC

Avanti Research - A Croda Brand

동의어(들):

L-α-lysophosphatidylcholine (Egg, Chicken)

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

보기 변경

제품정보 (DICE 배송 시 비용 별도)

CAS 번호:
MDL number:
UNSPSC Code:
12352211
NACRES:
NA.25
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의


assay

>99% (LPC; may contain up to 10% of the 2-LPC isomer, TLC)

form

powder

packaging

pkg of 1 × 1 g (830071P-1g), pkg of 1 × 200 mg (830071P-200mg), pkg of 1 × 25 mg (830071P-25mg), pkg of 1 × 500 mg (830071P-500mg)

manufacturer/tradename

Avanti Research - A Croda Brand

lipid type

phosphoglycerides
phospholipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

[P](=O)([O-])(OC[C@H](O)COC(=O)CCCCCCCCCCCCCCC)OCC[N+](C)(C)C

InChI

1S/C24H50NO7P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-24(27)30-21-23(26)22-32-33(28,29)31-20-19-25(2,3)4/h23,26H,5-22H2,1-4H3/t23-/m1/s1

InChI key

ASWBNKHCZGQVJV-HSZRJFAPSA-N

Application

Egg Lyso PC has been used for the preparation of liposomes. It has also been used as a lipid standard for liquid chromatography-mass spectrometry (LC-MS).

Packaging

20 mL Clear Glass Screw Cap Vial (830071P-1g)
20 mL Clear Glass Screw Cap Vial (830071P-500mg)
5 mL Amber Glass Screw Cap Vial (830071P-200mg)
5 mL Amber Glass Screw Cap Vial (830071P-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC


저장 등급

11 - Combustible Solids



가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문



Amperometric post spike feet reveal most exocytosis is via extended kiss-and-run fusion
Mellander LJ, et al.
Scientific Reports, 2 (2012)
Amperometric post spike feet reveal most exocytosis is via extended kiss-and-run fusion
Mellander LJ, et al.
Scientific reports, 2 (2012)
Padma Iyer et al.
PloS one, 7(8), e42627-e42627 (2012-08-24)
Primary open-angle glaucoma is the second leading cause of blindness in the United States and is commonly associated with elevated intraocular pressure (IOP) resulting from diminished aqueous humor (AH) drainage through the trabecular pathway. Developing effective therapies for increased IOP